AVDL — Avadel Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $847.44m
- $773.66m
- $169.12m
- 32
- 15
- 36
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 29.37 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.48 | ||
| Price to Tang. Book | 14.86 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.74% | ||
| Return on Equity | -60.46% | ||
| Operating Margin | -25.07% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 22.33 | n/a | n/a | 27.96 | 169.12 | 249.58 | 330.28 | 23.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +706.52 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Directors
- Geoffrey Glass NEC (47)
- Gregory Divis CEO (54)
- Thomas McHugh CFO (56)
- Richard Kim OTH (52)
- Eric Ende IND (52)
- Mark McCamish IND (69)
- Linda Palczuk IND (59)
- Peter Thornton IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 1st, 2017
- Public Since
- January 16th, 1952
- No. of Shareholders
- 130
- No. of Employees
- 188
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 96,629,435
- Address
- Block 10-1 Blanchardstown Corporate Park, DUBLIN, 15
- Web
- https://www.avadel.com/
- Phone
- +353 19015201
- Contact
- Courtney Turiano
- Auditors
- Deloitte & Touche LLP
Upcoming Events for AVDL
Avadel Pharmaceuticals PLC Annual Shareholders Meeting
Q2 2025 Avadel Pharmaceuticals PLC Earnings Release
Similar to AVDL
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avidity Biosciences
NASDAQ Global Market
FAQ
What is the Avadel Pharmaceuticals share price?
As of Today at 19:26 UTC, shares in Avadel Pharmaceuticals are trading at $8.77. This share price information is delayed by 15 minutes.
How has the Avadel Pharmaceuticals share price performed this year?
Shares in Avadel Pharmaceuticals last closed at $8.77 and the price had moved by -50.79% over the past 365 days. In terms of relative price strength the Avadel Pharmaceuticals share price has underperformed the S&P500 Index by -54.57% over the past year.
What are the analyst and broker recommendations for Avadel Pharmaceuticals?
The overall consensus recommendation for Avadel Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Avadel Pharmaceuticals dividend yield?
Avadel Pharmaceuticals does not currently pay a dividend.
Does Avadel Pharmaceuticals pay a dividend?
Avadel Pharmaceuticals does not currently pay a dividend.
When does Avadel Pharmaceuticals next pay dividends?
Avadel Pharmaceuticals does not currently pay a dividend.
How do I buy Avadel Pharmaceuticals shares?
To buy shares in Avadel Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Avadel Pharmaceuticals?
As of the previous close price of $8.77, shares in Avadel Pharmaceuticals had a market capitalisation of $847.44m.
Where are Avadel Pharmaceuticals shares listed?
Here are the trading details for Avadel Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: AVDL
What kind of share is Avadel Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Avadel Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Avadel Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Avadel Pharmaceuticals is $17.70. That is 101.82% above the last closing price of $8.77.
Analysts covering Avadel Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $0.09 for the next financial year.
Find out moreWhat is the trend in the Avadel Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avadel Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -28.23%.
As of the last closing price of $8.77, shares in Avadel Pharmaceuticals were trading -23.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Avadel Pharmaceuticals PE Ratio?
The Avadel Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 29.37. The shares last closed at $8.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Avadel Pharmaceuticals?
Avadel Pharmaceuticals' management team is headed by:
- Geoffrey Glass - NEC
- Gregory Divis - CEO
- Thomas McHugh - CFO
- Richard Kim - OTH
- Eric Ende - IND
- Mark McCamish - IND
- Linda Palczuk - IND
- Peter Thornton - IND